Melior Discovery
Melior Discovery is a pioneer in _in vivo_ phenotypic screening and a leader in drug repositioning. Its proprietary platform, _thera_ TRACE®, enables rapid and cost-effective identification of new therapeutic potential by systematically screening candidates in validated _in vivo_ disease models. The company offers a wide array of _in vivo_ pharmacology services across multiple therapeutic areas, including custom models and modifications. Melior is committed to uncovering the untapped value of therapeutics and has been serving the pharma industry since 2005, with thousands of completed studies and hundreds of compounds evaluated. It is DEA-licensed for Schedule I-V substances and is recognized for its scientific input, flexibility, and cost-effectiveness.
Industries
Nr. of Employees
small (1-50)
Melior Discovery
860 Springdale Drive Suite 500 Exton, PA 19341
Patents
Methods and formulations for modulating Lyn kinase activity and treating related disorders
US-12070461-B2
View DetailsMethods and formulations for modulating Lyn kinase activity and treating related disorders
US-11033548-B2
View DetailsMethods and formulations for modulating Lyn kinase activity and treating related disorders
US-10251883-B2
View DetailsMethods and formulations for modulating Lyn kinase activity and treating related disorders
US-9763945-B2
View DetailsMethods and formulations for modulating lyn kinase activity and treating related disorders
US-8835448-B2
View Details
Methods and formulations for modulating Lyn kinase activity and treating related disorders
US-12070461-B2
View DetailsMethods and formulations for modulating Lyn kinase activity and treating related disorders
US-11033548-B2
View DetailsMethods and formulations for modulating Lyn kinase activity and treating related disorders
US-10251883-B2
View DetailsMethods and formulations for modulating Lyn kinase activity and treating related disorders
US-9763945-B2
View DetailsMethods and formulations for modulating lyn kinase activity and treating related disorders
US-8835448-B2
View DetailsProducts
Multiplex in vivo phenotypic screening platform
A customizable, multiplexed screening platform that runs a coordinated array of validated animal models to identify new therapeutic indications and enable drug repositioning while minimizing animals and test article usage.
Multiplex in vivo phenotypic screening platform
A customizable, multiplexed screening platform that runs a coordinated array of validated animal models to identify new therapeutic indications and enable drug repositioning while minimizing animals and test article usage.
Services
On-site contract research conducting validated rodent efficacy studies across therapeutic areas with study design, execution, and data analysis.
Multiplexed in vivo phenotypic screening across arrays of validated models to identify new indications or repositioning opportunities while minimizing animal and test-article use.
Design and implement bespoke or literature-replicated animal models to meet unique project objectives, including chronic or modified protocols and operational validation for reproducibility.
Pharmacokinetic studies, bioanalysis (including HPLC methods), receptor occupancy and integration of PK/PD endpoints to support dose selection and interpretation.
In vivo imaging (bioluminescence/IVIS) and immunological assays including flow cytometry, multiplex cytokine panels, IHC and ELISA to characterize mechanism and pharmacodynamics.
Conducts abuse liability studies, seizure liability assays, general safety endpoints and other regulatory-relevant preclinical safety experiments.
On-site contract research conducting validated rodent efficacy studies across therapeutic areas with study design, execution, and data analysis.
Multiplexed in vivo phenotypic screening across arrays of validated models to identify new indications or repositioning opportunities while minimizing animal and test-article use.
Design and implement bespoke or literature-replicated animal models to meet unique project objectives, including chronic or modified protocols and operational validation for reproducibility.
Pharmacokinetic studies, bioanalysis (including HPLC methods), receptor occupancy and integration of PK/PD endpoints to support dose selection and interpretation.
In vivo imaging (bioluminescence/IVIS) and immunological assays including flow cytometry, multiplex cytokine panels, IHC and ELISA to characterize mechanism and pharmacodynamics.
Conducts abuse liability studies, seizure liability assays, general safety endpoints and other regulatory-relevant preclinical safety experiments.
Expertise Areas
- Preclinical in vivo pharmacology
- Phenotypic screening and drug repurposing
- Neuropharmacology and behavioral pharmacology
- Oncology preclinical evaluation
Key Technologies
- In vivo phenotypic screening
- Multiplex animal-model screening arrays
- Bioluminescence / IVIS imaging
- Flow cytometry (FACS)
News & Updates
Melior was recognized as CRO of the Year by Life Sciences Review.
Merck acquired Modifi Bio, a cancer therapy developer, in 2024 for up to $1.3 billion.
GSK acquired Bellus, a company in the chronic cough market, in 2023 for $2 billion.
Soliton was acquired by Allergan in 2021 for $550 million.
NuEvolutions was acquired by Amgen in 2019 for $167 million.
Tolero was acquired by Sumitomo Dainippon Pharma in 2016 for $580 million.
Melior was recognized as CRO of the Year by Life Sciences Review.
Merck acquired Modifi Bio, a cancer therapy developer, in 2024 for up to $1.3 billion.
GSK acquired Bellus, a company in the chronic cough market, in 2023 for $2 billion.
Soliton was acquired by Allergan in 2021 for $550 million.
NuEvolutions was acquired by Amgen in 2019 for $167 million.
Tolero was acquired by Sumitomo Dainippon Pharma in 2016 for $580 million.